NYSE:PRGO
Perrigo Company plc Stock News
$31.94
+0.670 (+2.14%)
At Close: Apr 26, 2024
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
08:09am, Tuesday, 23'rd Apr 2024
DUBLIN , April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial res
Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth
05:49am, Tuesday, 09'th Apr 2024
After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and compariso
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors
04:59pm, Thursday, 04'th Apr 2024
CVS Caremark, the pharmacy benefit management subsidiary of CVS Health Corp , will add Perrigo's birth control pill to its preventive services oral contraceptives list and make it available at no cost
Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices
10:32am, Sunday, 03'rd Mar 2024
Underdogs stocks carry almost universal appeal. It's one thing to go with the rest of the crowd.
27 Upcoming Dividend Increases Including A Dividend King
12:15pm, Thursday, 29'th Feb 2024
A new list of 27 new dividend increases, including King Kimberly-Clark and three other champions.
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
01:35pm, Tuesday, 27'th Feb 2024
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations.
Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics
10:36am, Tuesday, 27'th Feb 2024
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compar
20 midcap stocks with 2024 upside ranging up to 62%, according to analysts
01:02pm, Tuesday, 26'th Dec 2023
When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After
Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying
12:28am, Wednesday, 15'th Nov 2023
Perrigo Company focuses on the consumer self-care market and aligns with the growing trend of investing in well-being products. The company has faced regulatory issues with its baby formula production
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View
01:32pm, Tuesday, 07'th Nov 2023
Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales.
Perrigo's stock tumbles 14% after sales miss and lowered guidance
06:51am, Tuesday, 07'th Nov 2023
Perrigo Co. Plc's stock PRGO, -0.97% fell 14% early Tuesday, after the consumer self-care and wellness products maker posted weaker-than-expected third-quarter sales and lowered its guidance. Dublin,
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
09:47am, Monday, 06'th Nov 2023
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
2 Fast Dividend Growers With Strong Outlooks
02:46pm, Wednesday, 25'th Oct 2023
Broadcom Inc. and Perrigo Company plc are two companies providing impressive dividend growth to their shareholders. Perrigo Company is a smaller pharmaceutical company focusing on over-the-counter hea
Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023
09:54am, Tuesday, 24'th Oct 2023
DUBLIN , Oct. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2023 financial resu
FDA warns three baby-formula makers about production violations
05:15pm, Wednesday, 30'th Aug 2023
The U.S. Food and Drug Administration said Wednesday it has sent warning letters to three baby-formula makers as part of what the agency called enhanced oversight of the product, which was plagued by